USA flag logo/image

An Official Website of the United States Government

Recombinant human lactoferrin to treat oral mucositis

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
71503
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
DE015914
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AGENNIX, INC.
AGENNIX, INC. 8 GREENWAY PLZ, STE 910 HOUSTON, TX 77046 0892
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: Yes
 
Phase 1
Fiscal Year: 2004
Title: Recombinant human lactoferrin to treat oral mucositis
Agency: HHS
Contract: 1R43DE015914-01
Award Amount: $349,929.00
 

Abstract:

DESCRIPTION: Oral mucositis is a major dose-limiting toxic effect of intensive cancer chemotherapy and radiotherapy. In addition to the morbidity directly caused by severe oral mucositis, it can cause secondary morbidities by limiting oral intake or even lead to dose reduction or delay in further cancer treatment. Mucositis can be caused directly by cytotoxic effects and indirectly by sustained neutropenia after cytostatic therapy. An impaired mucosal barrier predisposes patients to life-threatening septic complications during aplasia. The prevalence of an oral focus in febrile neutropenia has been reported in up to 30 percent of cases. Recombinant human lactoferrin (rhLF) has been shown in pre-clinical experiments to exhibit a combination of immunomodulatory, anti-inflammatory and anti-infective properties. Lactoferrin has been shown to (i) promote healing in several in-vitro and animal models; (ii) inhibit increases in gut permeability induced by irritant agents in animal models and in humans; (iii) decrease the permeability of the gut mucosa to bacteria; (iv) reduce mortality following oral bacterial challenge in animal models; and (v) decrease the severity of neutropenic fever in patients receiving myelosuppressive chemotherapy for acute myelogenous leukemia. These properties make rhLF a promising candidate to prevent and treat severe oral mucositis and to reduce its systemic infectious complications. Based on the above results, we propose a Phase IIa clinical trial in patients at risk of developing severe oral mucositis. The target population is patients undergoing aggressive chemotherapy for the treatment of acute myelogenous leukemia, a therapy known to cause a high incidence of severe mucositis. The patients will receive either rhLF or placebo following completion of the chemotherapy and we will evaluate the ability of rhLF to reduce the incidence, severity, or duration of the oral mucositis, and its effect on the incidence and severity of neutropenic fever. In addition to the results described above which support the potential efficacy of rhLF in oral mucositis, the drug has been shown to be safe and well tolerated, having been administered orally to 210 patients without a single drug-related serious adverse event. The support we are requesting will enable us to continue clinical development of this novel drug and bring it closer to use by patients.

Principal Investigator:

Atul D. Varadhachary
7135521091
AVARADHACHARY@AGENNIX.COM

Business Contact:

Rick Barsky
7135521091
RBARSKY@AGENNIX.COM
Small Business Information at Submission:

AGENNIX, INC.
AGENNIX, INC. 8 GREENWAY PLZ, STE 910 HOUSTON, TX 77046

EIN/Tax ID: 954405779
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No